{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:50:05Z","timestamp":1780527005888,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,17]]},"DOI":"10.7759\/cureus.42008","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T12:38:20Z","timestamp":1689597500000},"source":"Crossref","is-referenced-by-count":2,"title":["Therapy-Related Acute Promyelocytic Leukemia: A Case Report and a Review of Literature"],"prefix":"10.7759","author":[{"given":"Dawson","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari K","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Rajeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al.. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022, 140:1200-28. 10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.162","article-title":"Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration","author":"Ribeiro RC","year":"2006","unstructured":"Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program. 2006, 162-8. 10.1182\/asheducation-2006.1.162","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002","volume":"19","author":"Yamamoto JF","year":"2008","unstructured":"Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control. 2008, 19:379-90. 10.1007\/s10552-007-9097-2","journal-title":"Cancer Causes Control"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores GM","year":"2012","unstructured":"Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012, 119:34-43. 10.1182\/blood-2011-04-347872","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008","volume":"118","author":"Chen Y","year":"2012","unstructured":"Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer. 2012, 118:5811-8. 10.1002\/cncr.27623","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid","volume":"118","author":"Park JH","year":"2011","unstructured":"Park JH, Qiao B, Panageas KS, et al.. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011, 118:1248-54. 10.1182\/blood-2011-04-346437","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401722","article-title":"The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation","volume":"14","author":"Vickers M","year":"2000","unstructured":"Vickers M, Jackson G, Taylor P. The incidence of acute promyelocytic leukemia appears constant over most of a human lifespan, implying only one rate limiting mutation. Leukemia. 2000, 14:722-6. 10.1038\/sj.leu.2401722","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.163","article-title":"Increased body mass index is a risk factor for acute promyelocytic leukemia","volume":"2","author":"Kashanian SM","year":"2021","unstructured":"Kashanian SM, Li AY, Mustafa Ali M, et al.. Increased body mass index is a risk factor for acute promyelocytic leukemia. EJHaem. 2021, 2:33-9. 10.1002\/jha2.163","journal-title":"EJHaem"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.072","article-title":"Therapy-related acute promyelocytic leukemia","volume":"21","author":"Beaumont M","year":"2003","unstructured":"Beaumont M, Sanz M, Carli PM, et al.. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003, 21:2123-37. 10.1200\/JCO.2003.09.072","journal-title":"J Clin Oncol"},{"key":"ref11","unstructured":"Pathology Outlines. APL with PML::RARA. (2023). Accessed: 04\/19\/2023: https:\/\/www.pathologyoutlines.com\/topic\/leukemiaapl.html."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz MA","year":"2009","unstructured":"Sanz MA, Grimwade D, Tallman MS, et al.. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009, 113:1875-91. 10.1182\/blood-2008-04-150250","journal-title":"Blood"},{"key":"ref13","article-title":"A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF\/RARA gene rearrangements","volume":"96","author":"Sainty D","year":"2000","unstructured":"Sainty D, Liso V, Cant\u00f9-Rajnoldi A, et al.. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF\/RARA gene rearrangements. Blood. 2000, 96:1287-96.","journal-title":"Blood"},{"key":"ref14","article-title":"Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique, Groupe de Fran\u00e7ais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action \"Molecular Cytogenetic Diagnosis in Haematological Malignancies\"","volume":"96","author":"Grimwade D","year":"2000","unstructured":"Grimwade D, Biondi A, Mozziconacci MJ, et al.. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique, Groupe de Fran\u00e7ais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action \"Molecular Cytogenetic Diagnosis in Haematological Malignancies\". Blood. 2000, 96:1297-308.","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.3.1178","article-title":"PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors","volume":"91","author":"Chen Z","year":"1994","unstructured":"Chen Z, Guidez F, Rousselot P, et al.. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A. 1994, 91:1178-82. 10.1073\/pnas.91.3.1178","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V91.8.2631.2631_2631_2633","article-title":"Acute promyelocytic leukemia: relieving repression induces remission","volume":"91","author":"Collins SJ","year":"1998","unstructured":"Collins SJ. Acute promyelocytic leukemia: relieving repression induces remission. Blood. 1998, 91:2631-3.","journal-title":"Blood"},{"key":"ref17","article-title":"Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF\/RAR alpha patient","volume":"8","author":"Guidez F","year":"1994","unstructured":"Guidez F, Huang W, Tong JH, et al.. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF\/RAR alpha patient. Leukemia. 1994, 8:312-7.","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V83.1.10.10","article-title":"Acute promyelocytic leukemia: from genetics to treatment","volume":"83","author":"Grignani F","year":"1994","unstructured":"Grignani F, Fagioli M, Alcalay M, et al.. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994, 83:10-25.","journal-title":"Blood"},{"key":"ref19","article-title":"A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation","volume":"10","author":"Wells RA","year":"1996","unstructured":"Wells RA, Hummel JL, De Koven A, Zipursky A, Kirby M, Dub\u00e9 I, Kamel-Reid S. A new variant translocation in acute promyelocytic leukaemia: molecular characterization and clinical correlation. Leukemia. 1996, 10:735-40.","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/8.9.1741","article-title":"The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia","volume":"8","author":"Arnould C","year":"1999","unstructured":"Arnould C, Philippe C, Bourdon V, Gr goire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999, 8:1741-9. 10.1093\/hmg\/8.9.1741","journal-title":"Hum Mol Genet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.8.2637","article-title":"Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways","volume":"99","author":"Dong S","year":"2002","unstructured":"Dong S, Tweardy DJ. Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood. 2002, 99:2637-46. 10.1182\/blood.v99.8.2637","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V99.8.2635","article-title":"Acute promyelocytic leukemia: STATs, HATs, and HDACs","volume":"99","author":"Collins SJ","year":"2002","unstructured":"Collins SJ. Acute promyelocytic leukemia: STATs, HATs, and HDACs. Blood. 2002, 99:2635.","journal-title":"Blood"},{"key":"ref23","article-title":"Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients","volume":"94","author":"Niu C","year":"1999","unstructured":"Niu C, Yan H, Yu T, et al.. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999, 94:3315-24.","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3532","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity","volume":"107","author":"Mathews V","year":"2006","unstructured":"Mathews V, George B, Lakshmi KM, et al.. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006, 107:2627-32. 10.1182\/blood-2005-08-3532","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4006","article-title":"Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia","volume":"107","author":"Estey E","year":"2006","unstructured":"Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006, 107:3469-73. 10.1182\/blood-2005-10-4006","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia","volume":"106","author":"Hu J","year":"2009","unstructured":"Hu J, Liu YF, Wu CF, et al.. Long-term efficacy and safety of all-trans retinoic acid\/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009, 106:3342-7. 10.1073\/pnas.0813280106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0312","article-title":"Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience","volume":"100","author":"Pulsoni A","year":"2002","unstructured":"Pulsoni A, Pagano L, Lo Coco F, et al.. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002, 100:1972-6. 10.1182\/blood-2001-12-0312","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.78","article-title":"Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group","volume":"16","author":"Asou N","year":"1998","unstructured":"Asou N, Adachi K, Tamura J, et al.. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998, 16:78-85. 10.1200\/JCO.1998.16.1.78","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008272817839","article-title":"The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years","volume":"8","author":"Latagliata R","year":"1997","unstructured":"Latagliata R, Avvisati G, Lo Coco F, et al.. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Ann Oncol. 1997, 8:1273-5. 10.1023\/a:1008272817839","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(00)00017-6","article-title":"Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia","volume":"1","author":"Wang ZY","year":"2000","unstructured":"Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Lancet Oncol. 2000, 1:101-6. 10.1016\/s1470-2045(00)00017-6","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3536(96)80037-0","article-title":"Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment","volume":"9","author":"van Leeuwen FE","year":"1996","unstructured":"van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin Haematol. 1996, 9:57-85. 10.1016\/s0950-3536(96)80037-0","journal-title":"Baillieres Clin Haematol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2000.tb02147.x","article-title":"Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine","volume":"27","author":"Kageshita T","year":"2000","unstructured":"Kageshita T, Kuribayashi N, Ono T. Myelodysplastic syndrome following treatment of malignant melanoma with vincristine, ACNU, and dacarbazine. J Dermatol. 2000, 27:178-80. 10.1111\/j.1346-8138.2000.tb02147.x","journal-title":"J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML","volume":"117","author":"Kayser S","year":"2011","unstructured":"Kayser S, D\u00f6hner K, Krauter J, et al.. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011, 117:2137-45. 10.1182\/blood-2010-08-301713","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.041970","article-title":"Therapy-related acute promyelocytic leukemia","volume":"96","author":"Ravandi F","year":"2011","unstructured":"Ravandi F. Therapy-related acute promyelocytic leukemia. Haematologica. 2011, 96:493-5. 10.3324\/haematol.2011.041970","journal-title":"Haematologica"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.9048","article-title":"Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer","volume":"25","author":"Le Deley MC","year":"2007","unstructured":"Le Deley MC, Suzan F, Cutuli B, et al.. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007, 25:292-300. 10.1200\/JCO.2006.05.9048","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000013","article-title":"Biology and management of therapy-related acute promyelocytic leukemia","volume":"25","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Hasan SK, Montesinos P, Sanz MA. Biology and management of therapy-related acute promyelocytic leukemia. Curr Opin Oncol. 2013, 25:695-700. 10.1097\/CCO.0000000000000013","journal-title":"Curr Opin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290006044","article-title":"Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia","volume":"43","author":"Zompi S","year":"2002","unstructured":"Zompi S, Vigui\u00e9 F. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma. 2002, 43:275-80. 10.1080\/10428190290006044","journal-title":"Leuk Lymphoma"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordjournals.annonc.a059316","article-title":"Therapy-related acute promyelocytic leukemia with t(15;17) (q22;ql2) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature","volume":"6","author":"Hoffmann L","year":"1995","unstructured":"Hoffmann L, Moller P, Bjergaard-Redersen Waage JA, Pedersen M, Hirsch FR. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;ql2) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Annals of Oncology. 1995, 6:781-8.","journal-title":"Annals of Oncology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb03288.x","article-title":"Therapy-related acute promyelocytic leukaemia","volume":"86","author":"Bhavnani M","year":"1994","unstructured":"Bhavnani M, Azzawi SA, Yin JA, Lucas GS. Therapy-related acute promyelocytic leukaemia. Br J Haematol. 1994, 86:231-2. 10.1111\/j.1365-2141.1994.tb03288.x","journal-title":"Br J Haematol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.5031","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data","volume":"28","author":"Mathews V","year":"2010","unstructured":"Mathews V, George B, Chendamarai E, et al.. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010, 28:3866-71. 10.1200\/JCO.2010.28.5031","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2107","article-title":"Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia","volume":"29","author":"Ghavamzadeh A","year":"2011","unstructured":"Ghavamzadeh A, Alimoghaddam K, Rostami S, et al.. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011, 29:2753-7. 10.1200\/JCO.2010.32.2107","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27650","article-title":"Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia","volume":"119","author":"Zhang Y","year":"2013","unstructured":"Zhang Y, Zhang Z, Li J, et al.. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013, 119:115-25. 10.1002\/cncr.27650","journal-title":"Cancer"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013, 369:111-21. 10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412035","article-title":"Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia","volume":"371","author":"Zhu HH","year":"2014","unstructured":"Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med. 2014, 371:2239-41. 10.1056\/NEJMc1412035","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V94.4.1192","article-title":"A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group","volume":"94","author":"Fenaux P","year":"1999","unstructured":"Fenaux P, Chastang C, Chevret S, et al.. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999, 94:1192-200.","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V82.11.3241.3241","article-title":"Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group","volume":"82","author":"Fenaux P","year":"1993","unstructured":"Fenaux P, Le Deley MC, Castaigne S, et al.. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993, 82:3241-9.","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol","volume":"100","author":"Tallman MS","year":"2002","unstructured":"Tallman MS, Andersen JW, Schiffer CA, et al.. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002, 100:4298-302. 10.1182\/blood-2002-02-0632","journal-title":"Blood"},{"key":"ref48","article-title":"Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups","volume":"90","author":"Mandelli F","year":"1997","unstructured":"Mandelli F, Diverio D, Avvisati G, et al.. Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997, 90:1014-21.","journal-title":"Blood"},{"key":"ref49","article-title":"A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha-positive acute promyelocytic leukemia. PETHEMA group","volume":"94","author":"Sanz MA","year":"1999","unstructured":"Sanz MA, Mart\u00edn G, Ray\u00f3n C, et al.. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood. 1999, 94:3015-21.","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V93.12.4131","article-title":"Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial","volume":"93","author":"Burnett AK","year":"1999","unstructured":"Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999, 93:4131-43.","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1596","article-title":"Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group","volume":"24","author":"Ad\u00e8s L","year":"2006","unstructured":"Ad\u00e8s L, Chevret S, Raffoux E, et al.. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006, 24:5703-10. 10.1200\/JCO.2006.08.1596","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276196","article-title":"Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group","volume":"116","author":"Lo-Coco F","year":"2010","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010, 116:3171-9. 10.1182\/blood-2010-03-276196","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.047506","article-title":"Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia","volume":"97","author":"Iland H","year":"2012","unstructured":"Iland H, Bradstock K, Seymour J, et al.. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012, 97:227-34. 10.3324\/haematol.2011.047506","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/152711-therapy-related-acute-promyelocytic-leukemia-a-case-report-and-a-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:11Z","timestamp":1707509111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/152711-therapy-related-acute-promyelocytic-leukemia-a-case-report-and-a-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.42008","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,17]]}}}